Brief Introduction

Haohai is a high-tech biomedical enterprise focus on the R&D, manufacturing and marketing of biomedical materials primarily made of intraocular lens (IOL), medical sodium hyaluronate, medical chitosan and medical collagen. Meanwhile, Haohai also manufactures innovative drugs such as rhEGF that primarily utilize genetic engineering technology. These products have extensive clinical application covering four major business segments including ophthalmology, medical aesthetics and wound care, orthopedics, and general surgery.

Haohai intend to expend the portfolio of innovative, competitively positioned products through market-derived product development programs focusing on products that address rapidly growing clinical needs and selective acquisition of pharmaceutical or biomedical materials companies with a focus on products that have the potential for future commercialization and market in global market.

Since 2016, through a series of mergers and acquisitions, Haohai has extended its footprint to the whole IOL industry chain as follows: Haohai accessed the production of raw materials, mastered the R&D and production process and improved the downstream sales network. Currently, Haohai has a leading position in various business areas of biomedical materials:

In 2018, Haohai was one of the largest manufacturer in domestic IOL market at about 30% in sales volume. Meanwhile,Haohai was largest manufacturer in the ophthalmic viscoelstic device market, viscosupplementation product market and anti-adhesiton product market, with market share of 46.9%, 39.7% and 48.9%, respectively. Moreover, Haohai was the second largest manufacturer in the rhEGF market accounting for 20.4% of the market share.

In the future, Haohai will continue relying upon scientific and technological innovation to create a new engine of business, and contribute to the transformation and upgrading of domestic biomedical technology.

Company Overview

Full name Shanghai Haohai Biological Technology Co.,Ltd
Abbreviations /
Code 06826.HK/688366.SH
Founded 2007.01.24
Listing 2015.04.30/2019.10.30
Domicile No.5 Dongjing Road, Songjiang Industrial Zone, Shanghai, China
STAR Theme Biomedicine
CSRC Sector Pharmaceutical manufacturing
Has weighted voting rights structure? No



  2018 2017 2016
Earnings Per Share 2.59 2.33 1.91
R&D expenditure as a % of operating revenue 6.12% 5.64% 5.49%
Operating Revenue 1,558.45 1,354.45 861.21
Net Income 455.08 400.01 310.63

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 1,558.45 1,354.45 861.21
Operating Costs 1,117.80 943.72 521.31
Operating Income 526.54 462.32 340.97
Pretax Income 525.18 461.62 365.88
Income Tax 70.1 61.6 55.3
Net Income 455.08 400.01 310.63

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Current Assets-Total 2,292.56 2,385.23 2,487.42
Non-current Assets-Total 2,143.8 1,724.1 1,206.0
Total Assets 4,436.35 4,109.32 3,693.41
Current Liabilities-Total 451.32 477.76 536.16
Non-current Liabilities-Total 149.59 246.30 171.40
Total Liabilities 600.91 724.06 707.55
Stockholder's Equity
Share Capital 223.94 184.70 81.87
Retained Profits 1,681.34 1,270.39 973.56
Minority interests 223.94 184.70 81.87
Total Owners' Equity 3,835.45 3,385.26 2,985.86

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating 391.29 351.26 262.61
Net Cash Flows-Investing -794.64 -156.59 -1,519.37
Net Cash Flows-Financing -85.33 -96.48 -58.42

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
Jang Wei 44.45 27.77%
You Jie 28.80 17.99%
Lou Guoliang 9.50 5.94%
Shanghai Zhanze Corporate Management Partnership Enterprise (Limited Partnership) 6.47 4.04%
Hou Yongtai 6.00 3.75%
Wu Jianying 6.00 3.75%
Peng Jinhua 3.00 1.87%
Changxing Tonghao Investment Partnership (Limited Partnership) 3.00 1.87%
Tao Weidong 2.00 1.25%
Huang Ming 2.00 1.25%
Liu Yuanzhong 2.00 1.25%
30 Jun 2019

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.